OverviewChartNewsTraderScreen

BNP Paribas Knock-Out SNW/  DE000PD5YXL5  /

Frankfurt Zert./BNP
17/05/2024  18:20:52 Chg.-0.030 Bid19:14:21 Ask19:14:21 Underlying Strike price Expiration date Option type
2.690EUR -1.10% 2.720
Bid Size: 3,600		 2.770
Ask Size: 3,600		 SANOFI SA INHABER ... 62.7844 - 31/12/2078 Call
GlobeNewswire 13/05 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
TeleTrader 13/05 Europe mixed at open as CPI prints loom
GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 10/05 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 10/05 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 10/05 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 09/05 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 09/05 Europe opens mixed with BoE in focus
GlobeNewswire 08/05 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 07/05 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 02/05 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 02/05 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 30/04 Press Release: Annual General Meeting of April 30, 2024
TeleTrader 25/04 Europe opens mostly down after corporate earnings
TeleTrader 25/04 Europe down in premarket as financial results pour in
TeleTrader 25/04 Sanofi books net sales of €10.5B in Q1, up 2.4%
GlobeNewswire 25/04 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire 23/04 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire 17/04 IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire 17/04 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire 16/04 2024 DTA Summit Agenda is LIVE!!
GlobeNewswire 10/04 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 09/04 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire 29/03 Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update